No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon.
In the context of a trial studying intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Lambaréné, Gabon, children aged 18-30 months were followed up after having received their last dose at an age of 15 months. In the intention-to-treat population, the protective efficacy against all malaria episodes was -18.0 (95% confidence interval, -97.4 to 29.5; P = .529). The protective efficacy against first or only anemia episode was -45.3 (95% confidence interval, -234.5 to 36.3; P=.375). The protective efficacies were negative and were not statistically significant. These results do not appear to support the concept of a rebound effect after intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants. Clinical trials registration. NCT00167843.
Grobusch
Martin P
MP
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon. martin.grobusch@wits.ac.za
Gabor
Julian J
JJ
Aponte
John J
JJ
Schwarz
Norbert G
NG
Poetschke
Marc
M
Doernemann
Jenny
J
Schuster
Katharina
K
Koester
Kai B
KB
Profanter
Katharina
K
Borchert
Lea B
LB
Kurth
Florian
F
Pongratz
Peter
P
Issifou
Saadou
S
Lell
Bertrand
B
Kremsner
Peter G
PG
D000740:Anemia / Q000453:epidemiology / Q000517:prevention & control; D000962:Antimalarials / Q000627:therapeutic use*; D002675:Child, Preschool; D015331:Cohort Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005681:Gabon / Q000453:epidemiology; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D008288:Malaria / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D009017:Morbidity; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine